This week, AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how we are rapidly delivering on our science-led strategy for transformational cancer drug development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 2-6, with 100 company-sponsored and supported abstracts, including five Best-of-ASCO presentations, 11 oral presentations and eight poster discussions.
We are committed to advancing the science of oncology as one of our five Growth Platforms – with a focus on lung, ovarian, breast and blood cancers, and the goal of redefining cancer treatments to one day eliminate cancer as a cause of death.
AstraZeneca presents TAGRISSO® (osimertinib) data in patients with EGFR T790M-mutation positive lung cancer and central nervous system metastases
June 6, 2017
LYNPARZA™ (olaparib) significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer
June 4, 2017
AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2017